HCKPMAG-11K | MILLIPLEX® MAP Human Immuno-Oncology Checkpoint Protein Panel Magnetic Bead Panel - Immuno-Oncology Multiplex Assay

新着HCKPMAG-11K
キットを構成して価格をご確認ください。
クリックして印刷用に表示

概要

Replacement Information

主要スペック表

Analytes AvailableSpecies ReactivityKey ApplicationsDetection Methods
BTLA, CD27, CD28, CD40, CD80/B7-1, CD86/B7-2, CTLA-4, GITR, GITRL, HVEM, ICOS, LAG-3, PD-1, PD-L1, TIM-3, TLR-2 H Mplex Luminex xMAP
Description
Catalogue NumberHCKPMAG-11K
Trade Name
  • MILLIPLEX
DescriptionMILLIPLEX® MAP Human Immuno-Oncology Checkpoint Protein Panel Magnetic Bead Panel - Immuno-Oncology Multiplex Assay
OverviewThe MILLIPLEX® MAP Human Immuno-Oncology Checkpoint Protein Magnetic Bead Panel is a 16-plex kit to be used for the simultaneous quantification of any or all of the following analytes in serum, plasma and tissue culture samples: BTLA (B- and T-lymphocyte attenuator), CD27 (Cluster of differentiation 27), CD28 (Cluster of differentiation 28), CD40 (Cluster of differentiation 40), CD80/B7-1 (Cluster of differentiation 80/B7-1), CD86/B7-2 (Cluster of differentiation 86/B7-2), CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), GITRL (Ligand for receptor TNFRSF18/AITR/GITR), GITR (Glucocorticoid-induced TNFR-related protein), HVEM (Herpesvirus entry mediator), ICOS (Inducible T-cell costimulator), LAG-3 (Lymphocyte-activation gene 3), PD-L1 (Programmed death-ligand 1), PD-1 (Programmed cell death protein 1), TIM-3 (T-cell immunoglobulin and mucin-domain containing-3), and TLR-2 (Toll like receptor 2).
Background InformationImmune checkpoint inhibitors have been proven to be an effective method in improving antitumor immune response and saving lives. Many immune checkpoint proteins are expressed as soluble forms in circulation and in the tumor and tumor microenvironment, as putative immune-oncology biomarkers.
References
Product Information
Detection methodLuminex xMAP
ConfigurationDesign your multiplex kit by choosing available analytes within this panel.
Precision, %
  • BTLA: Intra-assay <5% CV; Inter-assay <10%
  • CD27: Intra-assay <5% CV; Inter-assay <10% CV
  • CD28: Intra-assay <5% CV; Inter-assay <10% CV
  • TIM-3: Intra-assay <5% CV; Inter-assay <10% CV
  • HVEM: Intra-assay <5% CV; Inter-assay <10% CV
  • CD40: Intra-assay <5% CV; Inter-assay <10% CV
  • GITR: Intra-assay <5% CV; Inter-assay <10% CV
  • LAG-3: Intra-assay <5% CV; Inter-assay <15% CV
  • TLR-2: Intra-assay <5% CV; Inter-assay <10% CV
  • GITRL: Intra-assay <5% CV; Inter-assay <10% CV
  • PD-1: Intra-assay <5% CV; Inter-assay <10% CV
  • CTLA-4: Intra-assay <5% CV; Inter-assay <10% CV
  • CD80/B7-1: Intra-assay <5% CV; Inter-assay <10% CV
  • CD86/B7-2: Intra-assay <5% CV; Inter-assay <10% CV
  • PD-L1: Intra-assay <5% CV; Inter-assay <10% CV
  • ICOS: Intra-assay <5% CV; Inter-assay <10% CV
Panel TypeMAGNETIC Circulating Cancer
Applications
ApplicationThe Human Immuno-Oncology Checkpoint Protein Panel, using the Luminex xMAP technology, enables the simultaneous analysis of 16 checkpoint protein biomarkers in human serum, plasma and cell culture samples.
Key Applications
  • Multiplexing
Application NotesFor optimal sensitivity, use an overnight (16-18 hour) incubation. Serum and plasma samples require (recommend) a 1:2 dilution with Assay Buffer. Tissue culture supernatants may be run neat or appropriately diluted in control medium. Each well requires 25 μL of sample, standard or control.
Biological Information
SpecificityCross-reactivity between the antibodies and any of the other analytes in this panel is non-detectable or negligible.
Species Reactivity
  • Human
Analytes Available
  • BTLA
  • CD27
  • CD28
  • CD40
  • CD80/B7-1
  • CD86/B7-2
  • CTLA-4
  • GITR
  • GITRL
  • HVEM
  • ICOS
  • LAG-3
  • PD-1
  • PD-L1
  • TIM-3
  • TLR-2
Assay PanelEverything you need in a single kit.
Cross ReactivityThere was no or negligible cross-reactivity between the antibodies for an analyte and any of the other analytes in this panel.
Accuracy
  • BTLA 96%
  • CD27 99%
  • CD28 97%
  • TIM-3 99%
  • HVEM 102%
  • CD40 98%
  • GITR 91%
  • LAG-3 100%
  • TLR-2 99%
  • GITRL 99%
  • PD-1 94%
  • CTLA-4 98%
  • CD80/B7-1 96%
  • CD86/B7-2 100%
  • PD-L1 97%
  • ICOS 101%
Physicochemical Information
Sensitivity
  • MinDC+2SD
  • BTLA: 49.9 pg/mL
  • CD27: 25.8 pg/mL
  • CD28: 100.4 pg/mL
  • TIM-3: 2.1 pg/mL
  • HVEM: 1.5 pg/mL
  • CD40: 3.6 pg/mL
  • GITR: 11.1 pg/mL
  • LAG-3: 89.9 pg/mL
  • TLR-2: 33.5 pg/mL
  • GITRL: 26.9 pg/mL
  • PD-1: 10.4 pg/mL
  • CTLA-4: 8.6 pg/mL
  • CD80/B7-1: 13.1 pg/mL
  • CD80/B7-2: 96.3 pg/mL
  • PD-L1: 3.2 pg/mL
  • ICOS: 48.2 pg/mL
Linearity of DilutionContact technical support for this information
Standard Curve Range
  • BTLA: 48.8 - 200,000 pg/mL
  • CD27: 24.4 - 100,000 pg/mL
  • CD28: 244 - 1,000,000 pg/mL
  • TIM-3: 4.88 - 20,000 pg/mL
  • HVEM: 2.44 - 10,000 pg/mL
  • CD40: 4.88 - 20,000 pg/mL
  • GITR: 4.88 - 20,000 pg/mL
  • LAG-3: 122 - 50,000 pg/mL
  • TLR-2: 73.2 - 300,000 pg/mL
  • GITRL: 24.4 - 100,000 pg/mL
  • PD-1: 24.4 - 100,000 pg/mL
  • CTLA-4: 12.2 - 50,000 pg/mL
  • CD80/B7-1: 12.2 - 50,000 pg/mL
  • CD86/B7-2: 73.2 - 300,000 pg/mL
  • PD-L1: 4.88 - 20,000 pg/mL
  • ICOS: 48.8 - 200,000 pg/mL
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Usage Statement
  • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Storage and Shipping Information
Storage ConditionsRecommended storage for kit components is 2 - 8°C.
Packaging Information
Material Size96-well plate
Material Package96 well plate
Transport Information
Supplemental Information
Specifications